124 related articles for article (PubMed ID: 34895935)
1. Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine.
Raw RK; Rees J; Kelly CA; Wroe C; Chadwick DR
Vaccine; 2022 Jan; 40(3):418-423. PubMed ID: 34895935
[TBL] [Abstract][Full Text] [Related]
2. Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine.
Raw RK; Rees J; Chadwick DR
PLOS Glob Public Health; 2023; 3(2):e0001053. PubMed ID: 36963011
[TBL] [Abstract][Full Text] [Related]
3. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
[TBL] [Abstract][Full Text] [Related]
4. Side effects among healthcare workers from a large Milan university hospital after second dose of BNT162b2 mRNA COVID-19 vaccine.
Borroni E; Consonni D; Cugno M; Lombardi A; Mangioni D; Bono P; Oggioni M; Uceda Renteria S; Bordini L; Nava CD; Letzgus M; Gentiloni Silverj F; Castaldi S; Rognoni M; Cavallieri D'Oro L; Carugno M; Riboldi L; Ceriotti F; Bandera A; Gori A; Pesatori AC
Med Lav; 2021 Dec; 112(6):477-485. PubMed ID: 34939617
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccination in patients with primary immunodeficiencies: an international survey on patient vaccine hesitancy and self-reported adverse events.
Pergent M; Haerynck F; Hoste L; Gardulf A
Front Immunol; 2023; 14():1166198. PubMed ID: 37143673
[TBL] [Abstract][Full Text] [Related]
6. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
7. Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.
Cheng Y; Li T; Zheng Y; Xu B; Bi Y; Hu Y; Zhou YH
Hum Vaccin Immunother; 2022 Nov; 18(5):2064134. PubMed ID: 35452357
[TBL] [Abstract][Full Text] [Related]
8. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
[TBL] [Abstract][Full Text] [Related]
9. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
10. Host factors and history of SARS-CoV-2 infection impact the reactogenicity of BNT162b2 mRNA vaccine: results from a cross-sectional survey on 7,014 workers in healthcare.
Ughi N; Del Gaudio F; Dicuonzo A; Orso M; Micheloni G; Puoti M; Pani A; Scaglione F; Zoppini L; Rossetti C; Epis OM; Bellavia G; Giroldi S; Moreno M; Bosio M
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7985-7996. PubMed ID: 34982462
[TBL] [Abstract][Full Text] [Related]
11. Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study.
Lee DS; Kim JW; Lee KL; Jung YJ; Kang HW
Int J Infect Dis; 2022 May; 118():173-182. PubMed ID: 35276381
[TBL] [Abstract][Full Text] [Related]
12. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
14. Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naïve and previously infected by SARS-CoV-2.
Chong-Valbuena A; De-Jesús-María I; Agurto-Ramírez A; Puchades-Gimeno F; Melero-García M
Vaccine; 2022 Jun; 40(28):3818-3820. PubMed ID: 35643563
[TBL] [Abstract][Full Text] [Related]
15. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
[TBL] [Abstract][Full Text] [Related]
16. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
Yavuz E; Günal Ö; Başbulut E; Şen A
J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
[TBL] [Abstract][Full Text] [Related]
18. BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
Vizcarra P; Haemmerle J; Velasco H; Velasco T; Fernández-Escribano M; Vallejo A; Casado JL
Vaccine; 2021 Dec; 39(51):7367-7374. PubMed ID: 34802792
[TBL] [Abstract][Full Text] [Related]
19. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
20. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
